Comparative oncology clinical trials play an important and growing role in cancer research and drug development efforts. These trials, typically conducted in companion (pet) dogs, allow assessment of novel anticancer agents and combination therapies in a veterinary clinical setting that supports serial biologic sample collections and exploration of dose, schedule and corresponding pharmacokinetic/pharmacodynamic relationships. Further, an intact immune system and natural co-evolution of tumour and microenvironment support exploration of novel immunotherapeutic strategies. Substantial improvements in our collective understanding of the molecular landscape of canine cancers have occurred in the past 10 years, facilitating translational research and supporting the inclusion of comparative studies in drug development. The value of the approach is demonstrated in various clinical trial settings, including single-agent or combination response rates, inhibition of metastatic progression and randomized comparison of multiple agents in a head-to-head fashion. Such comparative oncology studies have been purposefully included in the developmental plan for several US FDA-approved and up-and-coming anticancer drugs. Challenges for this field include keeping pace with technology and data dissemination/harmonization, improving annotation of the canine genome and immune system, and generation of canine-specific validated reagents to support integration of correlative biology within clinical trial efforts.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Scientific Reports Open Access 12 January 2023
Feasibility of circulating tumor DNA analysis in dogs with naturally occurring malignant and benign splenic lesions
Scientific Reports Open Access 15 April 2022
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
LeBlanc, A. K. et al. Perspectives from man’s best friend: National Academy of Medicine’s Workshop on Comparative Oncology. Sci. Transl Med. 8, 324ps325 (2016).
Khanna, C., London, C., Vail, D., Mazcko, C. & Hirschfeld, S. Guiding the optimal translation of new cancer treatments from canine to human cancer patients. Clin. Cancer Res. 15, 5671–5677 (2009).
Burton, J. & Khanna, C. The role of clinical trials in veterinary oncology. Vet. Clin. North Am. Small Anim. Pract. 44, 977–987 (2014).
Alvarez, C. E. Naturally occurring cancers in dogs: insights for translational genetics and medicine. ILAR J. 55, 16–45 (2014).
Duran-Struuck, R., Huang, C. A. & Matar, A. J. Cellular therapies for the treatment of hematological malignancies; swine are an ideal preclinical model. Front. Oncol. 9, 418 (2019).
Johnson, P. A. & Giles, J. R. The hen as a model of ovarian cancer. Nat. Rev. Cancer 13, 432–436 (2013).
van der Weyden, L. et al. Cross-species models of human melanoma. J. Pathol. 238, 152–165 (2016).
van Zeeland, Y. Rabbit oncology: diseases, diagnostics, and therapeutics. Vet. Clin. North Am. Exot. Anim. Pract. 20, 135–182 (2017).
Schachtschneider, K. M. et al. Oncopig soft-tissue sarcomas recapitulate key transcriptional features of human sarcomas. Sci. Rep. 7, 2624 (2017).
Schoemaker, N. J. Ferret oncology: diseases, diagnostics, and therapeutics. Vet. Clin. North Am. Exot. Anim. Pract. 20, 183–208 (2017).
Schiffman, J. D. & Breen, M. Comparative oncology: what dogs and other species can teach us about humans with cancer. Philos. Trans. R. Soc. Lond. B Biol. Sci. 370, 20140231 (2015).
Cannon, C. M. Cats, cancer and comparative oncology. Vet. Sci. 2, 111–126 (2015).
Gustafson, D. L., Duval, D. L., Regan, D. P. & Thamm, D. H. Canine sarcomas as a surrogate for the human disease. Pharmacol. Ther. 188, 80–96 (2018).
Gardner, H. L., Fenger, J. M. & London, C. A. Dogs as a model for cancer. Annu. Rev. Anim. Biosci. 4, 199–222 (2016).
Gordon, I., Paoloni, M., Mazcko, C. & Khanna, C. The comparative oncology trials consortium: using spontaneously occurring cancers in dogs to inform the cancer drug development pathway. PLoS Med. 6, e1000161 (2009).
Barutello, G. et al. Strengths and weaknesses of pre-clinical models for human melanoma treatment: dawn of dogs’ revolution for immunotherapy. Int. J. Mol. Sci. 19, 799 (2018).
Tarone, L. et al. Naturally occurring cancers in pet dogs as pre-clinical models for cancer immunotherapy. Cancer Immunol. Immunother. 68, 1839–1853 (2019).
Garden, O. A., Volk, S. W., Mason, N. J. & Perry, J. A. Companion animals in comparative oncology: One Medicine in action. Vet. J. 240, 6–13 (2018).
Page, R. et al. Conduct, oversight, and ethical considerations of clinical trials in companion animals with cancer: report of a workshop on best practice recommendations. J. Vet. Intern. Med. 30, 527–535 (2016).
Paoloni, M. & Khanna, C. Translation of new cancer treatments from pet dogs to humans. Nat. Rev. Cancer 8, 147–156 (2008).
LeBlanc, A. K., Mazcko, C. N. & Khanna, C. Defining the value of a comparative approach to cancer drug development. Clin. Cancer Res. 22, 2133–2138 (2016).
Paoloni, M. C. et al. Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFα to cancer vasculature. PLoS ONE 4, e4972 (2009).
Thamm, D. H. Canine cancer: strategies in experimental therapeutics. Front. Oncol. 9, 1257 (2019).
Pryer, N. K. et al. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors. Clin. Cancer Res. 9, 5729–5734 (2003).
Khanna, C. & Gordon, I. Catching cancer by the tail: new perspectives on the use of kinase inhibitors. Clin. Cancer Res. 15, 3645–3647 (2009).
Liao, A. T. et al. Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood 100, 585–593 (2002).
London, C. A. et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin. Cancer Res. 9, 2755–2768 (2003).
Lin, T. Y. et al. The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors. Exp. Hematol. 36, 1266–1277 (2008).
London, C. A. et al. KTN0158, a humanized anti-KIT monoclonal antibody, demonstrates biologic activity against both normal and malignant canine mast cells. Clin. Cancer Res. 23, 2565–2574 (2017).
Davis, B. W. & Ostrander, E. A. Domestic dogs and cancer research: a breed-based genomics approach. ILAR J. 55, 59–68 (2014).
Lindblad-Toh, K. et al. Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature 438, 803–819 (2005). This work presents the first comprehensive description and annotation of the canine genome, which enables further study in canine comparative genomics.
Ostrander, E. A., Dreger, D. L. & Evans, J. M. Canine cancer genomics: lessons for canine and human health. Annu. Rev. Anim. Biosci. 7, 449–472 (2019).
Ostrander, E. A. et al. Dog10K: an international sequencing effort to advance studies of canine domestication, phenotypes and health. Natl Sci. Rev. 6, 810–824 (2019).
Megquier, K. et al. BarkBase: epigenomic annotation of canine genomes. Genes 10, 433 (2019).
Paoloni, M. et al. Prospective molecular profiling of canine cancers provides a clinically relevant comparative model for evaluating personalized medicine (PMed) trials. PLoS ONE 9, e90028 (2014).
London, C. A. et al. Impact of toceranib/piroxicam/cyclophosphamide maintenance therapy on outcome of dogs with appendicular osteosarcoma following amputation and carboplatin chemotherapy: a multi-institutional study. PLoS ONE 10, e0124889 (2015).
Turner, H. et al. Prognosis for dogs with stage III osteosarcoma following treatment with amputation and chemotherapy with and without metastasectomy. J. Am. Vet. Med. Assoc. 251, 1293–1305 (2017).
Bishop, M. W., Janeway, K. A. & Gorlick, R. Future directions in the treatment of osteosarcoma. Curr. Opin. Pediatr. 28, 26–33 (2016).
Lagmay, J. P. et al. Outcome of patients with recurrent osteosarcoma enrolled in seven phase II trials through children’s cancer group, pediatric oncology group, and children’s oncology group: learning from the past to move forward. J. Clin. Oncol. 34, 3031–3038 (2016).
Selmic, L. E., Burton, J. H., Thamm, D. H., Withrow, S. J. & Lana, S. E. Comparison of carboplatin and doxorubicin-based chemotherapy protocols in 470 dogs after amputation for treatment of appendicular osteosarcoma. J. Vet. Intern. Med. 28, 554–563 (2014).
Roberts, R. D. et al. Provocative questions in osteosarcoma basic and translational biology: a report from the Children’s Oncology Group. Cancer 125, 3514–3525 (2019).
Fenger, J. M., London, C. A. & Kisseberth, W. C. Canine osteosarcoma: a naturally occurring disease to inform pediatric oncology. ILAR J. 55, 69–85 (2014).
Grohar, P. J., Janeway, K. A., Mase, L. D. & Schiffman, J. D. Advances in the treatment of pediatric bone sarcomas. Am. Soc. Clin. Oncol. Educ. Book 37, 725–735 (2017).
Paoloni, M. et al. Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics 10, 625 (2009). This comparative array-based assessment of gene expression shows that canine and human osteosarcomas are indistinguishable from each other from a transcriptomic standpoint, and that canine osteosarcoma could inform novel gene and target discovery in human osteosarcoma.
Angstadt, A. Y. et al. Characterization of canine osteosarcoma by array comparative genomic hybridization and RT-qPCR: signatures of genomic imbalance in canine osteosarcoma parallel the human counterpart. Genes Chromosomes Cancer 50, 859–874 (2011).
Angstadt, A. Y., Thayanithy, V., Subramanian, S., Modiano, J. F. & Breen, M. A genome-wide approach to comparative oncology: high-resolution oligonucleotide aCGH of canine and human osteosarcoma pinpoints shared microaberrations. Cancer Genet. 205, 572–587 (2012).
Scott, M. C. et al. Molecular subtypes of osteosarcoma identified by reducing tumor heterogeneity through an interspecies comparative approach. Bone 49, 356–367 (2011).
Gröbner, S. et al. The landscape of genomic alterations across childhood cancers. Nature 555, 321–327 (2018).
Gardner, H. L. et al. Canine osteosarcoma genome sequencing identifies recurrent mutations in DMD and the histone methyltransferase gene SETD2. Commun. Biol. 2, 266 (2019). This study provides a comprehensive whole-genome, whole-exome and transcriptomic assessment of canine osteosarcoma, providing further evidence of similarities between human and canine osteosarcomas.
Chen, X. et al. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep. 7, 104–112 (2014).
Shao, Y. W. et al. Cross-species genomics identifies DLG2 as a tumor suppressor in osteosarcoma. Oncogene 38, 291–298 (2019).
Sakthikumar, S. et al. SETD2 is recurrently mutated in whole-exome sequenced canine osteosarcoma. Cancer Res. 78, 3421–3431 (2018).
Perry, J. A. et al. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proc. Natl Acad. Sci. USA 111, E5564–E5573 (2014).
Roy, J., Wycislo, K. L., Pondenis, H., Fan, T. M. & Das, A. Comparative proteomic investigation of metastatic and non-metastatic osteosarcoma cells of human and canine origin. PLoS ONE 12, e0183930 (2017).
Kovac, M. et al. Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency. Nat. Commun. 6, 8940 (2015).
Gulhan, D. C., Lee, J. J., Melloni, G. E. M., Cortes-Ciriano, I. & Park, P. J. Detecting the mutational signature of homologous recombination deficiency in clinical samples. Nat. Genet. 51, 912–919 (2019).
Withers, S. S. et al. Metastatic immune infiltrates correlate with those of the primary tumour in canine osteosarcoma. Vet. Comp. Oncol. 17, 242–252 (2019).
Sorenson, L., Fu, Y., Hood, T., Warren, S. & McEachron, T. A. Targeted transcriptional profiling of the tumor microenvironment reveals lymphocyte exclusion and vascular dysfunction in metastatic osteosarcoma. Oncoimmunology 8, e1629779 (2019).
Wu, C. C. et al. Immuno-genomic landscape of osteosarcoma. Nat. Commun. 11, 1008 (2020).
Bergman, P. J. Cancer immunotherapies. Vet. Clin. North Am. Small Anim. Pract. 49, 881–902 (2019).
Maekawa, N. et al. A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma. Sci. Rep. 7, 8951 (2017).
Endo-Munoz, L. et al. Auranofin improves overall survival when combined with standard of care in a pilot study involving dogs with osteosarcoma. Vet. Comp. Oncol. 18, 206–213 (2020).
Mason, N. J. et al. Immunotherapy with a HER2-targeting listeria induces HER2-specific immunity and demonstrates potential therapeutic effects in a phase I trial in canine osteosarcoma. Clin. Cancer Res. 22, 4380–4390 (2016).
Sayles, L. C. et al. Genome-informed targeted therapy for osteosarcoma. Cancer Discov. 9, 46–63 (2019).
Richards, K. L. & Suter, S. E. Man’s best friend: what can pet dogs teach us about non-Hodgkin’s lymphoma? Immunol. Rev. 263, 173–191 (2015).
Marconato, L. et al. Conformity and controversies in the diagnosis, staging and follow-up evaluation of canine nodal lymphoma: a systematic review of the last 15 years of published literature. Vet. Comp. Oncol. 15, 1029–1040 (2017).
Cozzi, M. et al. Canine nodal marginal zone lymphoma: descriptive insight into the biological behaviour. Vet. Comp. Oncol. 16, 246–252 (2018).
Davies, O. et al. Prognostic significance of clinical presentation, induction and rescue treatment in 42 cases of canine centroblastic diffuse large B-cell multicentric lymphoma in the United Kingdom. Vet. Comp. Oncol. 16, 276–287 (2018).
Dias, J. N. R. et al. Canine multicentric lymphoma exhibits systemic and intratumoral cytokine dysregulation. Vet. Immunol. Immunopathol. 218, 109940 (2019).
Ewing, T. S., Pieper, J. B. & Stern, A. W. Prevalence of CD20+ cutaneous epitheliotropic T-cell lymphoma in dogs: a retrospective analysis of 24 cases (2011–2018) in the USA. Vet. Dermatol. 30, 51-e14 (2019).
Ito, D., Frantz, A. M. & Modiano, J. F. Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: recent progress and applications. Vet. Immunol. Immunopathol. 159, 192–201 (2014).
Seelig, D. M., Avery, A. C., Ehrhart, E. J. & Linden, M. A. The comparative diagnostic features of canine and human lymphoma. Vet. Sci. 3, 11 (2016).
Modiano, J. F., Breen, M., Valli, V. E., Wojcieszyn, J. W. & Cutter, G. R. Predictive value of p16 or Rb inactivation in a model of naturally occurring canine non-Hodgkin’s lymphoma. Leukemia 21, 184–187 (2007).
Morton, L. M. et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 107, 265–276 (2006).
DeWeerdt, S. How dogs are teaching researchers new tricks for treating cancer. Nature 563, S50–S51 (2018).
Wolf-Ringwall, A. et al. Prospective evaluation of flow cytometric characteristics, histopathologic diagnosis and clinical outcome in dogs with naive B-cell lymphoma treated with a 19-week CHOP protocol. Vet. Comp. Oncol. 18, 342–352 (2020).
Burton, J. H. et al. NCI Comparative Oncology Program testing of non-camptothecin indenoisoquinoline topoisomerase I inhibitors in naturally occurring canine lymphoma. Clin. Cancer Res. 24, 5830–5840 (2018).
Yamazaki, H. et al. Effects of toceranib phosphate (Palladia) monotherapy on multidrug resistant lymphoma in dogs. J. Vet. Med. Sci. 7, 1225–1229 (2017).
London, C. A. et al. Phase I evaluation of STA-1474, a prodrug of the novel HSP90 inhibitor ganetespib, in dogs with spontaneous cancer. PLoS ONE 6, e27018 (2011).
Habineza Ndikuyeze, G. et al. A phase I clinical trial of systemically delivered NEMO binding domain peptide in dogs with spontaneous activated B-cell like diffuse large B-cell lymphoma. PLoS ONE 9, e95404 (2014).
Honigberg, L. A. et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl Acad. Sci. USA 107, 13075–13080 (2010).
Vail, D. M. et al. Assessment of GS-9219 in a pet dog model of non-Hodgkin’s lymphoma. Clin. Cancer Res. 15, 3503–3510 (2009).
Dias, J. N. R. et al. The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma. Oncotarget 9, 28586–28598 (2018).
Kalakonda, N. et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol. 7, e511–e522 (2020).
Sadowski, A. R. et al. Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. BMC Vet. Res. 14, 250 (2018).
London, C. A. et al. Preclinical evaluation of the novel, orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study. PLoS ONE 9, e87585 (2014).
Thomas, R. et al. Refining tumor-associated aneuploidy through ‘genomic recoding’ of recurrent DNA copy number aberrations in 150 canine non-Hodgkin lymphomas. Leuk. Lymphoma 52, 1321–1335 (2011).
Ferraresso, S. et al. DNA methylation profiling reveals common signatures of tumorigenesis and defines epigenetic prognostic subtypes of canine diffuse large B-cell lymphoma. Sci. Rep. 7, 11591 (2017).
Gaurnier-Hausser, A. & Mason, N. J. Assessment of canonical NF-κB activity in canine diffuse large B-cell lymphoma. Methods Mol. Biol. 1280, 469–504 (2015).
Seelig, D. M. et al. Constitutive activation of alternative nuclear factor κB pathway in canine diffuse large B-cell lymphoma contributes to tumor cell survival and is a target of new adjuvant therapies. Leuk. Lymphoma 58, 1702–1710 (2017).
Richards, K. L. et al. Gene profiling of canine B-cell lymphoma reveals germinal center and postgerminal center subtypes with different survival times, modeling human DLBCL. Cancer Res. 73, 5029–5039 (2013). This study highlights the molecular phenotyping, based on comparative gene expression profiling, of canine lymphoma and how it relates to human DLBCL.
Gaurnier-Hausser, A., Patel, R., Baldwin, A. S., May, M. J. & Mason, N. J. NEMO-binding domain peptide inhibits constitutive NF-κB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma. Clin. Cancer Res. 17, 4661–4671 (2011).
Avery, A. C. The genetic and molecular basis for canine models of human leukemia and lymphoma. Front. Oncol. 10, 23 (2020).
Bushell, K. R. et al. Genetic inactivation of TRAF3 in canine and human B-cell lymphoma. Blood 125, 999–1005 (2015).
Elvers, I. et al. Exome sequencing of lymphomas from three dog breeds reveals somatic mutation patterns reflecting genetic background. Genome Res. 25, 1634–1645 (2015).
Zain, J. M. Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management. Am. J. Hematol. 94, 929–946 (2019).
Heavican, T. B. et al. Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. Blood 133, 1664–1676 (2019).
Harris, L. J. et al. Canine CD4+ T-cell lymphoma identified by flow cytometry exhibits a consistent histomorphology and gene expression profile. Vet. Comp. Oncol. 17, 253–264 (2019).
McDonald, J. T. et al. Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panel. Oncotarget 9, 22693–22702 (2018).
Panjwani, M. K. et al. Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma. Oncoimmunology 9, 1676615 (2020).
Panjwani, M. K. et al. Feasibility and safety of RNA-transfected CD20-specific chimeric antigen receptor T cells in dogs with spontaneous B cell lymphoma. Mol. Ther. 24, 1602–1614 (2016).
Marconato, L. et al. Opportunities and challenges of active immunotherapy in dogs with B-cell lymphoma: a 5-year experience in two veterinary oncology centers. J. Immunother. Cancer 7, 146 (2019).
Rue, S. M. et al. Identification of a candidate therapeutic antibody for treatment of canine B-cell lymphoma. Vet. Immunol. Immunopathol. 164, 148–159 (2015).
Mizuno, T. et al. Generation of a canine anti-canine CD20 antibody for canine lymphoma treatment. Sci. Rep. 10, 11476 (2020).
Haran, K. P. et al. Generation and validation of an antibody to canine CD19 for diagnostic and future therapeutic purposes. Vet. Pathol. 57, 241–252 (2020).
Shapiro, S. G. et al. Canine urothelial carcinoma: genomically aberrant and comparatively relevant. Chromosome Res. 23, 311–331 (2015).
Dhawan, D., Hahn, N. M., Ramos-Vara, J. A. & Knapp, D. W. Naturally-occurring canine invasive urothelial carcinoma harbors luminal and basal transcriptional subtypes found in human muscle invasive bladder cancer. PLoS Genet. 14, e1007571 (2018). This paper provides a comprehensive description of histologic subtypes and molecular features of canine urothelial carcinoma, relating these findings to human bladder cancer.
Knapp, D. W. et al. Naturally-occurring invasive urothelial carcinoma in dogs, a unique model to drive advances in managing muscle invasive bladder cancer in humans. Front. Oncol. 9, 1493 (2019).
Jack, S. et al. A novel, safe, fast and efficient treatment for Her2-positive and negative bladder cancer utilizing an EGF–anthrax toxin chimera. Int. J. Cancer 146, 449–460 (2020).
Fazekas-Singer, J. et al. Development of a radiolabeled caninized anti-EGFR antibody for comparative oncology trials. Oncotarget 8, 83128–83141 (2017).
Nagaya, T. et al. Near infrared photoimmunotherapy targeting bladder cancer with a canine anti-epidermal growth factor receptor (EGFR) antibody. Oncotarget 9, 19026–19038 (2018).
Fulkerson, C. M., Dhawan, D., Ratliff, T. L., Hahn, N. M. & Knapp, D. W. Naturally occurring canine invasive urinary bladder cancer: a complementary animal model to improve the success rate in human clinical trials of new cancer drugs. Int. J. Genomics 2017, 6589529 (2017).
Mohammed, S. I. et al. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res. 62, 356–358 (2002).
Dhawan, D. et al. Effects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder. Mol. Cancer Ther. 9, 1371–1377 (2010).
Sabichi, A. L. et al. A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. Cancer Prev. Res. 4, 1580–1589 (2011).
Chand, D. et al. Immune checkpoint B7x (B7-H4/B7S1/VTCN1) is over expressed in spontaneous canine bladder cancer: the first report and its implications in a preclinical model. Bladder Cancer 5, 63–71 (2019).
Decker, B. et al. Homologous mutation to human BRAF V600E is common in naturally occurring canine bladder cancer — evidence for a relevant model system and urine-based diagnostic test. Mol. Cancer Res. 13, 993–1002 (2015).
Mochizuki, H., Kennedy, K., Shapiro, S. G. & Breen, M. BRAF mutations in canine cancers. PLoS ONE 10, e01295344 (2015).
Longo, T. et al. Targeted exome sequencing of the cancer genome in patients with very high-risk bladder cancer. Eur. Urol. 70, 714–717 (2016).
Sorenmo, K. U. in Withrow & MacEwen’s Small Animal Clinical Oncology (eds Thamm D. H., Liptak J. M. & Vail D.) 604-625 (Elsevier, 2020).
Sorenmo, K. U. et al. Canine mammary gland tumours; a histological continuum from benign to malignant; clinical and histopathological evidence. Vet. Comp. Oncol. 7, 162–172 (2009).
Nguyen, F. et al. Canine invasive mammary carcinomas as models of human breast cancer. Part 1: natural history and prognostic factors. Breast Cancer Res. Treat. 167, 635–648 (2018).
Raposo, T. P. et al. Comparative aspects of canine and human inflammatory breast cancer. Semin. Oncol. 44, 288–300 (2017).
Carvalho, M. I. et al. A comparative approach of tumor-associated inflammation in mammary cancer between humans and dogs. Biomed. Res. Int. 2016, 4917387 (2016).
Varallo, G. R. et al. Prognostic phenotypic classification for canine mammary tumors. Oncol. Lett. 18, 6545–6553 (2019).
Lutful Kabir, F. M., Alvarez, C. E. & Bird, R. C. Canine mammary carcinomas: a comparative analysis of altered gene expression. Vet. Sci. 3, 1 (2015).
Lee, K. H., Hwang, H. J., Noh, H. J., Shin, T. J. & Cho, J. Y. Somatic mutation of PIK3CA (H1047R) is a common driver mutation hotspot in canine mammary tumors as well as human breast cancers. Cancers 11, 2006 (2019).
Vasan, N., Toska, E. & Scaltriti, M. Overview of the relevance of PI3K pathway in HR-positive breast cancer. Ann. Oncol. 30, x3–x11 (2019).
Burrai, G. P. et al. Investigation of HER2 expression in canine mammary tumors by antibody-based, transcriptomic and mass spectrometry analysis: is the dog a suitable animal model for human breast cancer? Tumour Biol. 36, 9083–9091 (2015).
Pena, L. et al. Canine mammary tumors: a review and consensus of standard guidelines on epithelial and myoepithelial phenotype markers, HER2, and hormone receptor assessment using immunohistochemistry. Vet. Pathol. 51, 127–145 (2014).
Lorch, G. et al. Identification of recurrent activating her2 mutations in primary canine pulmonary adenocarcinoma. Clin. Cancer Res. 25, 5866–5877 (2019). This study describes the molecular landscape of canine lung cancer, reporting on the similarities to and differences from human NSCLC.
Seung, B. J., Cho, S. H., Kim, S. H., Lim, H. Y. & Sur, J. H. Quantitative analysis of HER2 mRNA expression by RNA in situ hybridization in canine mammary gland tumors: comparison with immunohistochemistry analysis. PLoS ONE 15, e0229031 (2020).
Thumser-Henner, P., Nytko, K. J. & Rohrer Bley, C. Mutations of BRCA2 in canine mammary tumors and their targeting potential in clinical therapy. BMC Vet. Res. 16, 30 (2020).
Saba, C. et al. A comparative oncology study of iniparib defines its pharmacokinetic profile and biological activity in a naturally-occurring canine cancer model. PLoS ONE 11, e0149194 (2016).
Connolly, N. P. et al. Cross-species transcriptional analysis reveals conserved and host-specific neoplastic processes in mammalian glioma. Sci. Rep. 8, 1180 (2018).
Miller, A. D., Miller, C. R. & Rossmeisl, J. H. Canine primary intracranial cancer: a clinicopathologic and comparative review of glioma, meningioma, and choroid plexus tumors. Front. Oncol. 9, 1151 (2019).
Thomas, R. et al. ‘Putting our heads together’: insights into genomic conservation between human and canine intracranial tumors. J. Neurooncol. 94, 333–349 (2009).
Filley, A. et al. Immunologic and gene expression profiles of spontaneous canine oligodendrogliomas. J. Neurooncol 137, 469–479 (2018).
Dickinson, P. J. et al. Chromosomal aberrations in canine gliomas define candidate genes and common pathways in dogs and humans. J. Neuropathol. Exp. Neurol. 75, 700–710 (2016).
Koehler, J. W. et al. A revised diagnostic classification of canine glioma: towards validation of the canine glioma patient as a naturally occurring preclinical model for human glioma. J. Neuropathol. Exp. Neurol. 77, 1039–1054 (2018).
Ostrom, Q. T., Cote, D. J., Ascha, M., Kruchko, C. & Barnholtz-Sloan, J. S. Adult glioma incidence and survival by race or ethnicity in the United States from 2000 to 2014. JAMA Oncol. 4, 1254–1262 (2018).
Chen, R., Smith-Cohn, M., Cohen, A. L. & Colman, H. Glioma subclassifications and their clinical significance. Neurotherapeutics 14, 284–297 (2017).
LeBlanc, A. K. et al. Creation of an NCI Comparative Brain Tumor Consortium: informing the translation of new knowledge from canine to human brain tumor patients. NeuroOncol. 18, 1209–1218 (2016).
Amin, S. B. et al. Comparative molecular life history of spontaneous canine and human gliomas. Cancer Cell 37, 243–257.e247 (2020). This study comprehensively describes the genomic landscape of >80 canine gliomas, demonstrating that canine glioma more closely resembles paediatric rather than adult human glioma.
Reitman, Z. J. et al. IDH1 and IDH2 hotspot mutations are not found in canine glioma. Int. J. Cancer 127, 245–246 (2010).
Latouche, E. L. et al. High-frequency irreversible electroporation for intracranial meningioma: a feasibility study in a spontaneous canine tumor model. Technol. Cancer Res. Treat. 17, 1533033818785285 (2018).
Schlein, L. J. et al. Immunohistochemical characterization of procaspase-3 overexpression as a druggable target with PAC-1, a procaspase-3 activator, in canine and human brain cancers. Front. Oncol. 9, 96 (2019).
Dickinson, P. J. et al. Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging: laboratory investigation. J. Neurosurg. 108, 989–998 (2008).
Debinski, W., Dickinson, P., Rossmeisl, J. H., Robertson, J. & Gibo, D. M. New agents for targeting of IL-13RA2 expressed in primary human and canine brain tumors. PLoS ONE 8, e77719 (2013).
MacDiarmid, J. A. et al. Targeted doxorubicin delivery to brain tumors via minicells: proof of principle using dogs with spontaneously occurring tumors as a model. PLoS ONE 11, e0151832 (2016).
Sayour, E. J. et al. Personalized tumor RNA loaded lipid-nanoparticles prime the systemic and intratumoral milieu for response to cancer immunotherapy. Nano. Lett. 18, 6195–6206 (2018).
Olin, M. R. et al. Treatment combining CD200 immune checkpoint inhibitor and tumor-lysate vaccination after surgery for pet dogs with high-grade glioma. Cancers 11, 137 (2019).
Olin, M. R. et al. Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art. Crit. Rev. Immunol. 34, 399–432 (2014).
Andersen, B. M. et al. Vaccination for invasive canine meningioma induces in situ production of antibodies capable of antibody-dependent cell-mediated cytotoxicity. Cancer Res. 73, 2987–2997 (2013).
Pluhar, G. E. et al. Anti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapy. Vaccine 28, 3371–3378 (2010).
Yin, Y. et al. Checkpoint blockade reverses anergy in IL-13Rα2 humanized scFv-based CAR T cells to treat murine and canine gliomas. Mol. Ther. Oncolytics 11, 20–38 (2018).
Lee, B., Clarke, D., Watson, M. & Laver, T. Retrospective evaluation of a modified human lung cancer stage classification in dogs with surgically excised primary pulmonary carcinomas. Vet. Comp. Oncol. https://doi.org/10.1111/vco.12582 (2020).
Hellmann, M. D. et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N. Engl. J. Med. 381, 2020–2031 (2019).
Dafni, U., Tsourti, Z., Vervita, K. & Peters, S. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis. Lung Cancer 134, 127–140 (2019).
D’Arcangelo, M., D’Incecco, A. & Cappuzzo, F. Rare mutations in non-small-cell lung cancer. Future Oncol. 9, 699–711 (2013).
Govindan, R. et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 150, 1121–1134 (2012).
Nishiya, A. T. et al. Comparative aspects of canine melanoma. Vet. Sci. 3, 7 (2016).
Simpson, R. M. et al. Sporadic naturally occurring melanoma in dogs as a preclinical model for human melanoma. Pigment. Cell Melanoma Res. 27, 37–47 (2014).
Hernandez, B. et al. Naturally occurring canine melanoma as a predictive comparative oncology model for human mucosal and other triple wild-type melanomas. Int. J. Mol. Sci. 19, 394 (2018).
Hendricks, W. P. D. et al. Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis. PLoS Genet. 14, e1007589 (2018).
Prouteau, A. & Andre, C. Canine melanomas as models for human melanomas: clinical, histological, and genetic comparison. Genes 10, 501 (2019).
Wong, K. et al. Cross-species genomic landscape comparison of human mucosal melanoma with canine oral and equine melanoma. Nat. Commun. 10, 353 (2019). This report provides an overview of shared genomic lesions from humans, horses and dogs, demonstrating biologic convergence despite differences in upstream driver mutational events.
Poorman, K. et al. Comparative cytogenetic characterization of primary canine melanocytic lesions using array CGH and fluorescence in situ hybridization. Chromosome Res. 23, 171–186 (2015).
Wei, B. R. et al. Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma. Pigment. Cell Melanoma Res. 29, 643–655 (2016).
Hayward, N. K. et al. Whole-genome landscapes of major melanoma subtypes. Nature 545, 175–180 (2017).
Fowles, J. S., Denton, C. L. & Gustafson, D. L. Comparative analysis of MAPK and PI3K/AKT pathway activation and inhibition in human and canine melanoma. Vet. Comp. Oncol. 13, 288–304 (2013).
Hartley, G. et al. Immune regulation of canine tumour and macrophage PD-L1 expression. Vet. Comp. Oncol. 15, 534–549 (2017).
Dow, S. A role for dogs in advancing cancer immunotherapy research. Front. Immunol. 10, 2935 (2019).
Klingemann, H. Immunotherapy for dogs: running behind humans. Front. Immunol. 9, 133 (2018).
Bergeron, L. M. et al. Comparative functional characterization of canine IgG subclasses. Vet. Immunol. Immunopathol. 157, 31–41 (2014). This work is the only comprehensive, comparative description of the functional subclasses of the canine IgG family, which highlights similarities and differences with humans.
Hartley, G., Elmslie, R., Dow, S. & Guth, A. Checkpoint molecule expression by B and T cell lymphomas in dogs. Vet. Comp. Oncol. 16, 352–360 (2018).
Coy, J., Caldwell, A., Chow, L., Guth, A. & Dow, S. PD-1 expression by canine T cells and functional effects of PD-1 blockade. Vet. Comp. Oncol. 15, 1487–1502 (2017).
Kumar, S. R. et al. Programmed death ligand 1 is expressed in canine B cell lymphoma and downregulated by MEK inhibitors. Vet. Comp. Oncol. 15, 1527–1536 (2017).
Pinheiro, D. et al. Phenotypic and functional characterization of a CD4+CD25highFOXP3high regulatory T-cell population in the dog. Immunology 132, 111–122 (2011).
Wu, Y. et al. Phenotypic characterisation of regulatory T cells in dogs reveals signature transcripts conserved in humans and mice. Sci. Rep. 9, 13478 (2019).
Hutchison, S. et al. Characterization of myeloid-derived suppressor cells and cytokines GM-CSF, IL-10 and MCP-1 in dogs with malignant melanoma receiving a GD3-based immunotherapy. Vet. Immunol. Immunopathol. 216, 109912 (2019).
Paoloni, M. et al. Defining the pharmacodynamic profile and therapeutic index of NHS-IL12 immunocytokine in dogs with malignant melanoma. PLoS ONE 10, e0129954 (2015).
Yasuda, N., Masuda, K., Tsukui, T., Teng, A. & Ishii, Y. Identification of canine natural CD3-positive T cells expressing an invariant T-cell receptor α chain. Vet. Immunol. Immunopathol. 132, 224–231 (2009).
Park, J. S. et al. Canine cancer immunotherapy studies: linking mouse and human. J. Immunother. Cancer 4, 97 (2016).
Overgaard, N. H. et al. Of mice, dogs, pigs, and men: choosing the appropriate model for immuno-oncology research. ILAR J. 59, 247–262 (2018).
Biller, B. J., Elmslie, R. E., Burnett, R. C., Avery, A. C. & Dow, S. W. Use of FoxP3 expression to identify regulatory T cells in healthy dogs and dogs with cancer. Vet. Immunol. Immunopathol. 116, 69–78 (2007).
Weiss D. J. in Schalm’s Veterinary Hematology (eds Weiss, D. J., Wardrop, K. J. & Schalm, O. W.) 1206 (Wiley-Blackwell, 2011).
Lepone, L. M. et al. Analyses of 123 peripheral human immune cell subsets: defining differences with age and between healthy donors and cancer patients not detected in analysis of standard immune cell types. J. Circ. Biomark 5, 5 (2016).
Withers, S. S. et al. Association of macrophage and lymphocyte infiltration with outcome in canine osteosarcoma. Vet. Comp. Oncol. 17, 49–60 (2019).
Biller, B. J., Guth, A., Burton, J. H. & Dow, S. W. Decreased ratio of CD8+ T cells to regulatory T cells associated with decreased survival in dogs with osteosarcoma. J. Vet. Intern. Med. 24, 1118–1123 (2010).
Gingrich, A. A., Modiano, J. F. & Canter, R. J. Characterization and potential applications of dog natural killer cells in cancer immunotherapy. J. Clin. Med. 8, 1802 (2019).
Graves, S. S. et al. Development and characterization of a canine-specific anti-CD94 (KLRD-1) monoclonal antibody. Vet. Immunol. Immunopathol. 211, 10–18 (2019).
Goulart, M. R. et al. Phenotypic and transcriptomic characterization of canine myeloid-derived suppressor cells. Sci. Rep. 9, 3574 (2019). This report describes canine MDSCs from both morphologic and gene expression contexts.
Hlavaty, S. I. et al. Bacterial killing activity of polymorphonuclear myeloid-derived suppressor cells isolated from tumor-bearing dogs. Front. Immunol. 10, 2371 (2019).
Chen, B. et al. Predicting HLA class II antigen presentation through integrated deep learning. Nat. Biotech. 37, 1332–1343 (2019).
Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217–221 (2017).
Kumai, T., Fan, A., Harabuchi, Y. & Celis, E. Cancer immunotherapy: moving forward with peptide T cell vaccines. Curr. Opin. Immunol. 47, 57–63 (2017).
Kennedy, L. J. et al. Nomenclature for factors of the dog major histocompatibility system (DLA), 2000: second report of the ISAG DLA Nomenclature Committee. Tissue Antigens 58, 55–70 (2001).
Ross, P. et al. The canine MHC class Ia allele DLA-88*508:01 presents diverse self- and canine distemper virus-origin peptides of varying length that have a conserved binding motif. Vet. Immunol. Immunopathol. 197, 76–86 (2018).
Ross, P., Holmes, J. C., Gojanovich, G. S. & Hess, P. R. A cell-based MHC stabilization assay for the detection of peptide binding to the canine classical class I molecule, DLA-88. Vet. Immunol. Immunopathol. 150, 206–212 (2012).
Xiao, J. et al. Diversified anchoring features the peptide presentation of DLA-88*50801: first structural insight into domestic dog MHC class I. J. Immunol. 197, 2306–2315 (2016).
Venkataraman, G. M. et al. Thirteen novel canine dog leukocyte antigen-88 alleles identified by sequence-based typing. HLA 90, 165–170 (2017).
Nemec, P. S., Kapatos, A., Holmes, J. C. & Hess, P. R. The prevalent Boxer MHC class Ia allotype dog leukocyte antigen (DLA)-88*034:01 preferentially binds nonamer peptides with a defined motif. HLA 92, 403–407 (2018).
Ross, P. et al. Allelic diversity at the DLA-88 locus in Golden Retriever and Boxer breeds is limited. Tissue Antigens 80, 175–183 (2012).
Barth, S. M. et al. Characterization of the canine MHC class I DLA-88*50101 peptide binding motif as a prerequisite for canine T cell immunotherapy. PLoS ONE 11, e0167017 (2016).
Finocchiaro, L. M. E. & Glikin, G. C. Recent clinical trials of cancer immunogene therapy in companion animals. World J. Exp. Med. 7, 42–48 (2017).
Perales, M. A. et al. Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma. Mol. Ther. 16, 2022–2029 (2008).
Wolchok, J. D. et al. Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma. Mol. Ther. 15, 2044–2050 (2007).
Strauss, J. et al. First-in-human phase I trial of a tumor-targeted cytokine (NHS-IL12) in subjects with metastatic solid tumors. Clin. Cancer Res. 25, 99–109 (2019).
Canter, R. J. et al. Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial. J. Immunother. Cancer 5, 98 (2017).
Judge, S. J. et al. Blood and tissue biomarker analysis in dogs with osteosarcoma treated with palliative radiation and intra-tumoral autologous natural killer cell transfer. PLoS ONE 15, e0224775 (2020).
Knapp, D. W., Dhawan, D. & Ostrander, E. ‘Lassie,’ ‘Toto,’ and fellow pet dogs: poised to lead the way for advances in cancer prevention. Am. Soc. Clin. Oncol. Educ. Book https://doi.org/10.14694/EdBook_AM.2015.35.e667 (2015).
Serrano, D., Lazzeroni, M. & Bonanni, B. Cancer chemoprevention: much has been done, but there is still much to do. State of the art and possible new approaches. Mol. Oncol. 9, 1008–1017 (2015).
Li, J. et al. SETD2: an epigenetic modifier with tumor suppressor functionality. Oncotarget 7, 50719–50734 (2016).
Jiang, C., He, C., Wu, Z., Li, F. & Xiao, J. Histone methyltransferase SETD2 regulates osteosarcoma cell growth and chemosensitivity by suppressing Wnt/β-catenin signaling. Biochem. Biophys. Res. Commun. 502, 382–388 (2018).
Tagawa, M., Maekawa, N., Konnai, S. & Takagi, S. Evaluation of costimulatory molecules in peripheral blood lymphocytes of canine patients with histiocytic sarcoma. PLoS ONE 11, e0150030 (2016).
Shimizu, K. et al. Eomes transcription factor is required for the development and differentiation of invariant NKT cells. Commun. Biol. 2, 150 (2019).
North American Pet Health Insurance Association. Willis Towers Watson Actuary Consultants. State of the industry report https://naphia.org/about-the-industry/section-2-total-pets-insured/ (2020).
Mullin, C. & Clifford, C. A. Histiocytic sarcoma and hemangiosarcoma update. Vet. Clin. North Am. Small Anim. Pract. 49, 855–879 (2019).
Megquier, K. et al. Comparative genomics reveals shared mutational landscape in canine hemangiosarcoma and human angiosarcoma. Mol. Cancer Res. 17, 2410–2421 (2019). This paper describes the shared molecular features of malignant vascular tumours in dogs and humans, providing the first evidence that canine hemangiosarcoma could serve as a model for human angiosarcoma.
Takada, M. et al. Activating mutations in PTPN11 and KRAS in canine histiocytic sarcomas. Genes 10, 505 (2019).
Takada, M. et al. Targeting MEK in a translational model of histiocytic sarcoma. Mol. Cancer Ther. 17, 2439–2450 (2018).
Mingus, L. Canine cancer prevention vaccine study seeks participants https://cvmbs.source.colostate.edu/canine-cancer-prevention-vaccine-study-seeks-participants/ (2019).
Guy, M. K. et al. The Golden Retriever Lifetime Study: establishing an observational cohort study with translational relevance for human health. Philos. Trans. R. Soc. Lond. B Biol. Sci. 370, 20140230 (2015).
The authors thank W. Hendricks, P. Choyke and N. Mason for their critical review of this manuscript. They thank J. Meyer for artistic input and technical assistance with the figures, and A. Cherukuri for assistance with manuscript preparation. This work was supported by the Intramural Program of the National Cancer Institute, National Institutes of Health (NIH; Z01-BC006161). The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the US Government.
The authors declare no competing interests.
Peer review information
Nature Reviews Cancer thanks M. Breen, S. Day and T. Fan for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
American Veterinary Medical Association: https://ebusiness.avma.org/aahsd/study_search.aspx
Brazilian Veterinary Cancer Society: https://abrovet.org.br
Cancer Moonshot Immunotherapy Trials Network in Comparative Oncology: https://dctd.cancer.gov/NewsEvents/20190327_canine_immunotherapy.htm
Clinical and Translational Science Award One Health Alliance: https://ctsaonehealthalliance.org
Comparative Oncology Program: https://ccr.cancer.gov/Comparative-Oncology-Program
Consortium for Canine Comparative Oncology: https://www.c3oncology.org
European Society of Veterinary Oncology: https://www.esvonc.com/Esvonc/national-veterinary-oncology-societies
Integrated Canine Data Commons: https://caninecommons.cancer.gov/#/
Japan Veterinary Cancer Society: http://www.jvcs.jp/english/
PRECINCT (Pre-medical Cancer Immunotherapy Network for Canine Trials): https://www.precinctnetwork.org
PRECINCT Project Synopses: https://www.precinctnetwork.org/project-synopses
Veterinary Cancer Society: www.vetcancersociety.org
- Array-based comparative genome hybridization
A genomic DNA hybridization technique that allows high-resolution analysis of copy number changes between two populations (such as normal versus tumour DNA).
- Homologous recombination DNA repair pathway
A repair mechanism in which an identical or nearly identical DNA sequence from a homologous chromosome is used as a template for the repair of a DNA break.
- Mismatch repair
A strand-specific mechanism for editing mismatched bases inserted in the daughter strand during DNA replication. This damage is repaired by recognition of the deformity caused by the mismatch.
- Blood–brain barrier
An interconnected network of capillaries that carries blood to the brain and spinal cord, but also blocks the passage of certain harmful substances.
- Convection-enhanced delivery
A technique that generates a pressure gradient at the tip of an infusion catheter to facilitate delivery of therapeutics to the central nervous system.
- Volume of drug distribution
A pharmacokinetic parameter that represents the theoretical volume into which a drug is distributed throughout the body based on solubility, charge, size and so forth.
About this article
Cite this article
LeBlanc, A.K., Mazcko, C.N. Improving human cancer therapy through the evaluation of pet dogs. Nat Rev Cancer 20, 727–742 (2020). https://doi.org/10.1038/s41568-020-0297-3
This article is cited by
Scientific Reports (2023)
Feasibility of circulating tumor DNA analysis in dogs with naturally occurring malignant and benign splenic lesions
Scientific Reports (2022)
Journal of Applied Genetics (2022)
Osteosarcoma tumor microenvironment: the key for the successful development of biologically relevant 3D in vitro models
In vitro models (2022)